founded in 1994, shanghai fosun pharmaceutical (group) co., ltd.* ("fosun pharma"; stock code: 600196. sh, 02196. hk) is a global innovation-driven pharmaceutical and healthcare industry group. fosun pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
fosun pharma is patient-centered and clinical needs-oriented. the company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. fosun pharma improves the research and clinical development capabilities of fic (first-in-class) and bic (best-in-class) new drugs as well as accelerates the r&d and launch of innovative technologies and products.
guided by the 4in strategy (innovation, internationalization, intelligentization, and integration), fosun pharma will uphold the development model of “innovation transformation, integrated operation and steady growth", with the mission of creating shareholder values through strengthening its independent r&d and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. fosun pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.
- 43,952 million
- fy2022 revenue
- 3,873 million
- fy2022 net profit after deducting extraordinary gain or loss attributable to owners of the parent
- 5,885 million
- fy2022 r&d expenditure
- global employees
- five-star (excellence)
- 2022 corporate social responsibility report rating
- msci esg rating
unit: rmb million